A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 125 participants.

Also called NCT03152552

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03152552
  • EudraCT 2016-003084-19
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Hungary, Ireland, Italy, Mexico, Netherlands, Norway, Poland, Puerto Rico, Singapore, South Africa, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03152552. Randomized; triple masking; primary purpose treatment. Start 2017-07-25 (actual); primary completion 2018-06-06 (actual). Results posted on 2019-08-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
Condition
Diabetes Mellitus and Heart Failure
Intervention (Drug)
LIK066
Intervention (Drug)
Placebo
Intervention (Drug)
Empagliflozin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03152552
Content hash
8c6c99a674a0a5c49bea50ea9f70dc8a52be14a0a86ef5fad210433a5d3f7921